{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:56:38Z","timestamp":1777517798459,"version":"3.51.4"},"reference-count":52,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,2,1]]},"abstract":"<jats:p>Objective. Human immunodeficiency virus type 1 (HIV-1)-associated progressive encephalopathy (PE) is a common and devastating complication of HIV-1 infection in children, whose risk factors have not yet been clearly defined. Regardless of the age of presentation, PE shortens life expectancy. Paradoxically, as survival of patients has been prolonged as a result of the use of antiretroviral therapy, the prevalence of PE has increased. Therefore, a predictive marker of PE emergence is critical. The objective of this study was to determine in an observational study whether any immunologic (CD4+ and CD8+ T-lymphocyte counts, monocyte counts) or virologic (viral load [VL], biological characteristics of viral isolates) marker might be predictive of PE and whether any particular marker may be involved in the timing of clinical onset of PE.<\/jats:p><jats:p>Methods. A total of 189 children who were vertically infected with HIV-1 were studied retrospectively, 58 of whom fulfilled criteria of the American Academy of Neurology for PE. T-lymphocyte subsets and monocytes in peripheral blood were quantified by flow cytometry. HIV-1 RNA was measured in plasma using a quantitative reverse transcriptase polymerase chain reaction assay. Demographic, clinical, and viro-immunologic characteristics in infants were compared with control groups using logistic regression. Proportions were compared using the \u03c72 test or Fisher exact test. For each child, immunologic and virologic markers were analyzed in parallel closely before clinical onset of PE and closely after PE onset and compared by using the Student t test for paired samples.<\/jats:p><jats:p>Results. Overall, mortality of 58 HIV-1-infected children who developed PE was significantly higher than of children who did not develop this complication. Blood CD8+ T-lymphocytes &amp;lt;25% in the first months of life suggested a relative risk of progressing to PE 4-fold higher than those with CD8+ &amp;gt;25% (95% confidence interval: 1.2\u201313.9) and remained statistically significant after adjustment for treatment. When we compared the PE-positive group with the acquired immunodeficiency syndrome (AIDS)\/PE-negative group (children who developed clinical category C and without neurologic manifestations) in a cross-sectional study within 12 months before PE or AIDS diagnosis, respectively, the %CD8+ T-lymphocytes were significantly lower in the PE-positive group. Normalized absolute counts of CD8+ T-lymphocytes with respect to seroreverting children were significantly lower in the group of children with encephalopathy with respect to the AIDS\/PE-negative group (data not shown). It is interesting that a statistically significant increase was observed in circulating monocyte percentages and absolute counts shortly before the first neurologic symptoms compared with values after PE was established and with those from HIV-1-infected controls. With respect to AIDS-related events, PE was strongly associated with anemia and lymphoid interstitial pneumonitis in the PE-positive group with respect to a group of children with AIDS but without PE.<\/jats:p><jats:p>Conclusion. HIV-1 infection of the central nervous system (CNS) remains an important clinical concern. The first step toward PE prevention in HIV-1-infected children should be directed at predicting risk of PE and thus the prompt and reliable identification of infants who are at risk for CNS disease progression. Low blood CD8+ T-lymphocytes is a strong early predictive marker of PE emergence in vertical HIV-1 infection. Indeed, among all of the immunologic and virologic variables assessed in this observational study, the only significant difference during the first months of life are the CD8+ T-lymphocytes. A peak of significantly higher peripheral monocytes before the onset of PE with respect to established PE has not been previously described, and strengthens the growing evidence that an increased traffic of monocytes to the brain may be a key factor in triggering neurologic symptoms. The suppression of HIV-1 replication is dependent on the presence of a relatively small number of HIV-1-specific CD8+ T-lymphocytes, and it is possible that the duration of the neurologically asymptomatic phase for any given child may depend mostly on the magnitude of specific CD8+ T-lymphocyte responses. Thus, a decrease of CD8+ T-lymphocytes would diminish the host capacity to control viral infection, as reported in animal models, enabling infected macrophages to cross the blood-brain barrier. Our results advocate the use of CD8+ T-lymphocyte and monocyte counts to follow-up HIV-1-infected children. We suggest that CD8+ T-lymphocytes may be the nexus for many different aspects of the disease, namely loss of control of HIV-1 replication determining higher VL, increased traffic of activated and\/or infected monocytes, spread of infection to immune sanctuaries, and finally clinical neurologic emergence of PE. Moreover, we suggest that CD8+ T-lymphocytes or\/and monocytes may be used as putative biological markers of neuropathogenicity. This might suggest their use in decision making of when to start more effective antiretroviral regimens for HIV-1 infection of the CNS and the need of new therapies either to preserve or to augment an adequate CD8+ T-lymphocyte immune response. Early detection of children who are at risk for developing PE is particularly important because aggressive highly active antiretroviral therapy improves neurologic symptoms, allows possible use of neuroprotective treatment to prevent further development of encephalopathy, and emphasizes the relevance of developing therapies aimed to enhance CD8+ T-lymphocyte function. In conclusion, the surrogate markers routinely used in clinical practice for HIV-1 infection (ie, CD4+ T-lymphocyte counts and VL) seem to be insufficient to evaluate the clinical involvement of the CNS. Other systemic markers, as the recent proposed markers for PE evolution (cerebrospinal fluid VL by lumbar puncture and brain atrophy by cerebral magnetic resonance imaging) are undoubtedly more invasive than measuring CD8+ T-lymphocyte and monocyte counts, when the neurologic manifestations of PE are still preventable.<\/jats:p>","DOI":"10.1542\/peds.111.2.e168","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:43:47Z","timestamp":1092444227000},"page":"e168-e175","source":"Crossref","is-referenced-by-count":50,"title":["Low Blood CD8+ T-Lymphocytes and High Circulating Monocytes Are Predictors of HIV-1-Associated Progressive Encephalopathy in Children"],"prefix":"10.1542","volume":"111","author":[{"given":"Silvia","family":"Sa\u0301nchez-Ramo\u0301n","sequence":"first","affiliation":[{"name":"Units of Neuroimmunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose\u0301","family":"M\u0363 Bello\u0301n","sequence":"additional","affiliation":[{"name":"Units of Neuroimmunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Resino","sequence":"additional","affiliation":[{"name":"Units of Neuroimmunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Canto\u0301-Nogue\u0301s","sequence":"additional","affiliation":[{"name":"Units of Neuroimmunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Gurbindo","sequence":"additional","affiliation":[{"name":"Immunopediatrics, Hospital General Universitario Gregorio Maran\u0303o\u0301n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose\u0301-Toma\u0301s","family":"Ramos","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital Doce de Octubre, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u0363Angeles","family":"Mun\u0303oz-Ferna\u0301ndez","sequence":"additional","affiliation":[{"name":"Units of Neuroimmunology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2003,2,1]]},"reference":[{"key":"2021121010095368000_R1","doi-asserted-by":"crossref","unstructured":"Tardieu M, Le Chenadec J, Persoz A, et al. HIV-1-related encephalopathy in infants compared with children and adults. French Pediatric HIV Infection Study and the SEROCO Group. Neurology.2000;54:1089\u20131095","DOI":"10.1212\/WNL.54.5.1089"},{"key":"2021121010095368000_R2","doi-asserted-by":"crossref","unstructured":"Mintz M. Clinical comparison of adult and pediatric NeuroAIDS. Adv Neuroimmunol.1994;4:207\u2013221","DOI":"10.1016\/S0960-5428(06)80259-7"},{"key":"2021121010095368000_R3","doi-asserted-by":"crossref","unstructured":"Cooper ER, Hanson C, Diaz C, et al. Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection. Women and Infants Transmission Study Group. J Pediatr.1998;132:808\u2013812","DOI":"10.1016\/S0022-3476(98)70308-7"},{"key":"2021121010095368000_R4","doi-asserted-by":"crossref","unstructured":"Lobato MN, Caldwell MB, Ng P, Oxtoby MJ. Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. Pediatric Spectrum of Disease Clinical Consortium. J Pediatr.1995;126:710\u2013715","DOI":"10.1016\/S0022-3476(95)70397-7"},{"key":"2021121010095368000_R5","doi-asserted-by":"crossref","unstructured":"McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology.1993;43:2245\u20132252","DOI":"10.1212\/WNL.43.11.2245"},{"key":"2021121010095368000_R6","doi-asserted-by":"crossref","unstructured":"Raskino C, Pearson DA, Baker CJ, et al. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team. Pediatrics.1999;104(3). Available at: www.pediatrics.org\/cgi\/content\/full\/104\/3\/e32","DOI":"10.1542\/peds.104.3.e32"},{"key":"2021121010095368000_R7","unstructured":"Englund JA, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. J Clin Invest.1997;99:2837\u20132841"},{"key":"2021121010095368000_R8","doi-asserted-by":"crossref","unstructured":"Melvin AJ, Mohan KM, Arcuino LA, Edelstein RE, Frenkel LM. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Clin Exp Immunol.1997;110:15\u201321","DOI":"10.1097\/00006454-199710000-00013"},{"key":"2021121010095368000_R9","doi-asserted-by":"crossref","unstructured":"Carcelain G, Debre P, Autran B. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol.2001;13:483\u2013488","DOI":"10.1016\/S0952-7915(00)00245-4"},{"key":"2021121010095368000_R10","doi-asserted-by":"crossref","unstructured":"Resino S, Sa\u0301nchez-Ramo\u0301n S, Bello\u0301n JM, Correa R, Abad ML, Munoz-Fernandez MA: Immunologic recovery after 3 years\u2019 antiretroviral therapy in HIV-1-infected children. AIDS.2002;16:483\u2013486","DOI":"10.1097\/00002030-200202150-00022"},{"key":"2021121010095368000_R11","doi-asserted-by":"crossref","unstructured":"Correa R, Munoz-Fernandez MA. Viral phenotype affects the thymic production of new T cells in HIV-1-infected children. AIDS.2001;15:1959\u20131963","DOI":"10.1097\/00002030-200110190-00007"},{"key":"2021121010095368000_R12","doi-asserted-by":"crossref","unstructured":"Husstedt IW, Frohne L, Bockenholt S, et al. Impact of highly active antiretroviral therapy on cognitive processing in HIV infection: cross-sectional and longitudinal studies of event-related potentials. AIDS Res Hum Retroviruses.2002;18:485\u2013490","DOI":"10.1089\/088922202317406628"},{"key":"2021121010095368000_R13","doi-asserted-by":"crossref","unstructured":"Price RW, Yiannoutsos CT, Clifford DB, et al. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS.1999;13:1677\u20131685","DOI":"10.1097\/00002030-199909100-00011"},{"key":"2021121010095368000_R14","doi-asserted-by":"crossref","unstructured":"Starace F, Dijkgraaf M, Houweling H, Postma M, Tramarin A: HIV-associated dementia: clinical, epidemiological and resource utilization issues. AIDS Care.1998;10(suppl 2):S113\u2013S121","DOI":"10.1080\/09540129850124226"},{"key":"2021121010095368000_R15","doi-asserted-by":"crossref","unstructured":"Gurbindo D, Resino S, Sa\u0301nchez-Ramo\u0301n S, Leo\u0301n JA, Mun\u0303oz-Ferna\u0301ndez MA. Correlation of viral load and CD8 T-lymphocytes with development of neurological manifestations in vertically HIV-1-infected infants. A prospective longitudinal study. Neuropediatrics.1999;30:197\u2013204","DOI":"10.1055\/s-2007-973490"},{"key":"2021121010095368000_R16","doi-asserted-by":"crossref","unstructured":"Mun\u0303oz-Ferna\u0301ndez MA, Obrego\u0301n E, Navarro J, et al. Relationship of virologic, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection. Pediatr Res.1996;40:597\u2013602","DOI":"10.1203\/00006450-199610000-00014"},{"key":"2021121010095368000_R17","unstructured":"Centers for Diseases Control Prevention. Revised classification system for HIV-1 infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep.1994;43:1\u201313"},{"key":"2021121010095368000_R18","doi-asserted-by":"crossref","unstructured":"Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology.1991;41:778\u2013785","DOI":"10.1212\/WNL.41.6.778"},{"key":"2021121010095368000_R19","doi-asserted-by":"crossref","unstructured":"Mun\u0303oz-Ferna\u0301ndez MA, Navarro J, Obrego\u0301n E, et al. Immunological and virological markers of disease progression in HIV-1 infected children. Acta Paediatr Suppl.1997;421:46\u201351","DOI":"10.1111\/j.1651-2227.1997.tb18319.x"},{"key":"2021121010095368000_R20","unstructured":"Resino S, Gurbindo D, Navarro J, et al. Prognostic markers in naive infants younger than two months of age with HIV-1 infection. Pediatr Relat Top (Padiatr Grenzgeb).1999;38:431\u2013446"},{"key":"2021121010095368000_R21","doi-asserted-by":"crossref","unstructured":"Resino S, Gurbindo D, Cano JM, Sa\u0301nchez-Ramo\u0301n S, Mun\u0303oz-Ferna\u0301ndez MA. Predictive markers of clinical outcome in vertically HIV-1-infected infants. A prospective longitudinal study. Pediatr Res.2000;47:509\u2013515","DOI":"10.1203\/00006450-200004000-00016"},{"key":"2021121010095368000_R22","doi-asserted-by":"crossref","unstructured":"Chase C, Ware J, Hittelman J, et al. Early cognitive and motor development among infants born to women infected with human immunodeficiency virus. Women and Infants Transmission Study Group. Pediatrics.2000;106(2). Available at: www.pediatrics.org\/cgi\/content\/full\/106\/2\/e25","DOI":"10.1542\/peds.106.2.e25"},{"key":"2021121010095368000_R23","doi-asserted-by":"crossref","unstructured":"Sa\u0301nchez-Ramo\u0301n S, Bello\u0301n JM, Resino S, et al. Low CD8+ T-lymphocyte counts predict HIV-1-associated progressive encephalopathy in children and may trigger CNS spread of HIV-1-activated monocytes. Presented at the 9th Conference on Retroviruses and Opportunistic Infections; February 24\u201328, 2002; Seattle, WA","DOI":"10.1542\/peds.111.2.e168"},{"key":"2021121010095368000_R24","doi-asserted-by":"crossref","unstructured":"Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. Unique monocyte subset in patients with AIDS dementia. Lancet.1997;349:692\u2013695","DOI":"10.1016\/S0140-6736(96)10178-1"},{"key":"2021121010095368000_R25","doi-asserted-by":"crossref","unstructured":"Gartner S. HIV infection and dementia. Science.2000;287:602\u2013604","DOI":"10.1126\/science.287.5453.602"},{"key":"2021121010095368000_R26","doi-asserted-by":"crossref","unstructured":"Epstein LG, Gendelman HE. Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann Neurol.1993;33:429\u2013436","DOI":"10.1002\/ana.410330502"},{"key":"2021121010095368000_R27","doi-asserted-by":"crossref","unstructured":"Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol.1995;38:755\u2013762","DOI":"10.1002\/ana.410380510"},{"key":"2021121010095368000_R28","doi-asserted-by":"crossref","unstructured":"McClernon DR, Lanier R, Gartner S, et al. RNA levels and patterns of zidovudine resistance. Neurology.2001;57:1396\u20131401","DOI":"10.1212\/WNL.57.8.1396"},{"key":"2021121010095368000_R29","doi-asserted-by":"crossref","unstructured":"Rouzioux C, Costagliola D, Burgard M, et al: Timing of mother-to-child HIV-1 transmission depends on maternal status. The HIV Infection in Newborns French Collaborative Study Group. AIDS.1993;7(suppl 2):S49\u2013S52","DOI":"10.1097\/00002030-199311002-00011"},{"key":"2021121010095368000_R30","doi-asserted-by":"crossref","unstructured":"Newell ML. Mechanisms and timing of mother-to-child transmission of HIV-1. AIDS.1998;12:831\u2013837","DOI":"10.1097\/00002030-199808000-00004"},{"key":"2021121010095368000_R31","unstructured":"Maldonado Y. Human immunodeficiency virus HIV and acquired immunodeficiency syndrome. In: Long SS, ed. Principle and Practice of Pediatric Infectious Disease. 4th ed. New York, NY: Churchill Livingstone; 1997:2169\u20132226"},{"key":"2021121010095368000_R32","doi-asserted-by":"crossref","unstructured":"Margolick JB, Munoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nat Med.1995;1:674\u2013680","DOI":"10.1038\/nm0795-674"},{"key":"2021121010095368000_R33","doi-asserted-by":"crossref","unstructured":"Phillips AN, Sabin CA, Elford J, et al. CD8 lymphocyte counts and serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte depletion during 8 years of follow-up. AIDS.1993;7:975\u2013980","DOI":"10.1097\/00002030-199307000-00011"},{"key":"2021121010095368000_R34","doi-asserted-by":"crossref","unstructured":"Anderson RE, Shiboski SC, Royce R, et al. CD8+ T lymphocytes and progression to AIDS in HIV-infected men: some observations. AIDS.1991;5:213\u2013215","DOI":"10.1097\/00002030-199102000-00013"},{"key":"2021121010095368000_R35","doi-asserted-by":"crossref","unstructured":"Buseyne F, Janvier G, Teglas JP, et al. Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age. J Infect Dis.1998;178:1019\u20131023","DOI":"10.1086\/515660"},{"key":"2021121010095368000_R36","doi-asserted-by":"crossref","unstructured":"Levacher M, Hulstaert F, Tallet S, et al. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol.1992;90:376\u2013382","DOI":"10.1111\/j.1365-2249.1992.tb05854.x"},{"key":"2021121010095368000_R37","doi-asserted-by":"crossref","unstructured":"Brouwers P, Civitello L, DeCarli C, Wolters P, Sei S. Cerebrospinal fluid viral load is related to cortical atrophy and not to intracerebral calcifications in children with symptomatic HIV disease. J Neurovirol.2000;6:390\u2013397","DOI":"10.3109\/13550280009018303"},{"key":"2021121010095368000_R38","doi-asserted-by":"crossref","unstructured":"Sopper S, Sauer U, Hemm S, et al. Protective role of the virus-specific immune response for development of severe neurologic signs in simian immunodeficiency virus-infected macaques. J Virol.1998;72:9940\u20139947","DOI":"10.1128\/JVI.72.12.9940-9947.1998"},{"key":"2021121010095368000_R39","doi-asserted-by":"crossref","unstructured":"Schutten M, van Baalen CA, Guillon C, et al. Macrophage tropism of human immunodeficiency virus type 1 facilitates in vivo escape from cytotoxic T-lymphocyte pressure. J Virol.2001;75:2706\u20132709","DOI":"10.1128\/JVI.75.6.2706-2709.2001"},{"key":"2021121010095368000_R40","doi-asserted-by":"crossref","unstructured":"Marcondes MC, Burudi EM, Huitron-Resendiz S, et al. Highly activated CD8+ T cells in the brain correlate with early central nervous system dysfunction in simian immunodeficiency virus infection. J Immunol.2001;167:5429\u20135438","DOI":"10.4049\/jimmunol.167.9.5429"},{"key":"2021121010095368000_R41","doi-asserted-by":"crossref","unstructured":"Katsetos CD, Fincke JE, Legido A, et al. Angiocentric CD3+ T-cell infiltrates in human immunodeficiency virus type 1-associated central nervous system disease in children. Clin Diagn Lab Immunol.1999;6:105\u2013114","DOI":"10.1128\/CDLI.6.1.105-114.1999"},{"key":"2021121010095368000_R42","doi-asserted-by":"crossref","unstructured":"Robertson K, Fiscus S, Kapoor C, et al. CSF, plasma viral load and HIV associated dementia. J Neurovirol.1998;4:90\u201394","DOI":"10.3109\/13550289809113485"},{"key":"2021121010095368000_R43","unstructured":"Stankoff B, Calvez V, Suarez S, et al. Plasma and cerebrospinal fluid human immunodeficiency virus type-1 (HIV- 1) RNA levels in HIV-related cognitive impairment. Eur J Neurol.1999;6:669\u2013675"},{"key":"2021121010095368000_R44","doi-asserted-by":"crossref","unstructured":"Mofenson LM, Korelitz J, Meyer WA 3rd, et al: The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis.1997;175:1029\u20131038","DOI":"10.1086\/516441"},{"key":"2021121010095368000_R45","doi-asserted-by":"crossref","unstructured":"Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med.1997;336:1337\u20131342","DOI":"10.1056\/NEJM199705083361901"},{"key":"2021121010095368000_R46","doi-asserted-by":"crossref","unstructured":"Mayaux MJ, Burgard M, Teglas JP, et al. Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. The French Pediatric HIV Infection Study Group. JAMA.1996;275:606\u2013610","DOI":"10.1001\/jama.275.8.606"},{"key":"2021121010095368000_R47","doi-asserted-by":"crossref","unstructured":"Blanche S, Newell M, Mayaux M, et al. Morbidity and mortality in European children vertically infected by HIV-1: the French prospective study and the European collaborative study. J Acquir Immune Defic Syndr Hum Retrovirol.1997;14:442\u2013450","DOI":"10.1097\/00042560-199704150-00008"},{"key":"2021121010095368000_R48","doi-asserted-by":"crossref","unstructured":"Resino S, Bello\u0301n JM, Sa\u0301nchez-Ramo\u0301n S, et al. Impact of antiretroviral protocols on dynamics of AIDS progression markers. Arch Dis Child.2002;86:119\u2013124","DOI":"10.1136\/adc.86.2.119"},{"key":"2021121010095368000_R49","doi-asserted-by":"crossref","unstructured":"Jime\u0301nez JL, Sa\u0301nchez-Ramo\u0301n S, Palomino S, Alcami\u0301 J, Mun\u0303oz-Ferna\u0301ndez MA. Where does free infective HIV-1 rebound come from?AIDS.2001;15:657","DOI":"10.1097\/00002030-200103300-00020"},{"key":"2021121010095368000_R50","doi-asserted-by":"crossref","unstructured":"Spivak JL, Bender BS, Quinn TC. Hematologic abnormalities in the acquired immune deficiency syndrome. Am J Med.1984;77:224\u2013228","DOI":"10.1016\/0002-9343(84)90695-8"},{"key":"2021121010095368000_R51","doi-asserted-by":"crossref","unstructured":"Poluektova LY, Munn DH, Persidsky Y, Gendelman HE. Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol.2002;168:3941\u20133949","DOI":"10.4049\/jimmunol.168.8.3941"},{"key":"2021121010095368000_R52","doi-asserted-by":"crossref","unstructured":"Ellis RJ, Gamst AC, Capparelli E, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology.2000;54:927\u2013936","DOI":"10.1212\/WNL.54.4.927"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/111\/2\/e168\/1007599\/pe020300e168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/111\/2\/e168\/1007599\/pe020300e168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:45:17Z","timestamp":1682747117000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/111\/2\/e168\/66771\/Low-Blood-CD8-T-Lymphocytes-and-High-Circulating"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,1]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2003,2,1]]},"published-print":{"date-parts":[[2003,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.111.2.e168","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,1]]}}}